ClinicalTrials.gg
RecruitingNCT07314892Psych-GvHDUpdated Jan 2, 2026

Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).

An observational study in GVHD, Chronic, GVHD - Graft-Versus-Host Disease and GVHD, sponsored by Medical University of Gdansk. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Medical University of Gdansk · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Bronchiolitis Obliterans Syndrome with a site in Poland — 3 open to participants now, 6 under way, 2 of them phase 3. Bronchiolitis Obliterans Syndrome · Poland.

Started
2025
the only one that year
Observational
Only one
of the 32
Registered
31st of 32
by date

Among the 32 studies in Bronchiolitis Obliterans Syndrome with a site in Poland, this one is the only one that started in 2025, is the only observational one, and was the 31st registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

3 of the 32 studies in Bronchiolitis Obliterans Syndrome with a site in Poland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Bronchiolitis Obliterans Syndrome with a site in Poland, or all of them as a file.
02

Study summary

This prospective observational study evaluates the association between psychiatric status, GvHD-related symptom severity, and health-related quality of life in patients with graft-versus-host disease. Standardized and validated assessment tools, including the Lee Symptom Scale, will be used to collect psychiatric, clinical, and demographic data.

Read the detailed description

Graft-versus-host disease (GvHD) is a significant complication following allogeneic hematopoietic stem cell transplantation and is associated with substantial symptom burden, impaired quality of life, and increased psychiatric morbidity. Despite its clinical relevance, the relationship between psychiatric status and the severity of GvHD-related symptoms remains insufficiently characterized.

This prospective observational study aims to systematically assess psychiatric status, symptom severity, and health-related quality of life in patients with GvHD using standardized and validated instruments. Demographic and clinical data will be collected to establish a comprehensive patient registry. The study will evaluate the association between psychiatric disorders and the intensity of GvHD-related symptoms, as measured by the Lee Symptom Scale, and will explore the bidirectional relationship between depressive symptoms and the clinical course of GvHD. The findings are expected to inform the development of evidence-based recommendations for therapeutic support aimed at improving clinical outcomes and quality of life in patients with GvHD.

03

Conditions studied

  • GVHD, Chronic
  • GVHD - Graft-Versus-Host Disease
  • GVHD
  • Quality of Life
  • Depression Disorders
  • Cognitive Impairments

Keywords

  • GvHD
  • depression
  • quality of life
  • Cognitive impairment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients aged 18 to 75 years, including both female and male participants, with a clinically confirmed diagnosis of graft-versus-host disease (GvHD). Participants are receiving specialist follow-up care at a bone marrow transplantation outpatient clinic and meet the predefined inclusion and exclusion criteria regarding clinical and psychiatric status.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with a clinically established diagnosis of (GvHD) receiving specialist follow-up care at the Bone Marrow Transplantation Outpatient Clinic, University Clinical Center (UCK), Gdańsk.

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric disorders precluding adequate cooperation, terminal-stage multiorgan failure, or refusal to provide for study participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • cGvHD and depression

    Patients with chronic graft-versus-host disease (GvHD) diagnosed with depressive disorders, adjustment disorders, or cognitive impairment, diagnosed according to ICD-10 and/or DSM-5 criteria.

  • cGvHD without depression

    Patients with chronic graft-versus-host disease (GvHD) without a diagnosis of depressive disorders, adjustment disorders, or cognitive impairment (control group).

06

What researchers measure

Primary outcomes

  1. Identification of depression as a factor associated with increased GvHD-related symptom burden and reduced health-related quality of life.

    Time frame: Baseline and follow-up assessments during the study period (up to 12 months).

  2. Assessment of therapeutic benefits associated with combined antidepressant treatment and psychotherapy, antidepressant treatment alone, and psychotherapy alone.

    Time frame: Baseline and follow-up assessments during the study period (up to 12 months).

  3. Support for the integration of systematic psychiatric assessment into standard multidisciplinary care protocols for patients with graft-versus-host disease.

    Time frame: Baseline and follow-up assessments during the study period (up to 12 months).

07

Study locations

1 of 1 sites recruiting
  • Department of Hematology and Transplantology
    Gdansk, Pomeranian Voivodeship 80-214, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2028, 36 months after the start.

Of 49 non-industry observational studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 75. This study's planned 36 months is below that.

Counting every sponsor, half of 57 studies reached it within 40 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 2, 2026
StartActual
Apr 8, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Oct 2028
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07314892
Responsible party
Jan Puchowski (MD, Medical University of Gdansk) — Principal investigator
First posted
Jan 2, 2026
Start date
Apr 8, 2025
Primary completion
Apr 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Jan 2, 2026

Study contacts

Jan Puchowski, M.D.
Contact
jpuchowski@uck.gda.pl
+48 58 584 43 40
Agnieszka Piekarska, MD PhD
Contact
agnieszka.piekarska@gumed.edu.pl
Jan Puchowski, MD
principal investigator · Department of Hematology and Transplantology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Agnieszka Piekarska, MD PhD
principal investigator · Department of Hematology and Transplantology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Karol Grabowski, MD PhD
study director · Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion